“…However, in SCLC, despite the identification of biomarkers, such as p53, β1-integrin, bcl-2, ERCC1, RRM1, IL-2, bax, BCRP and c-kit, the predictive and prognostic value of these makers is controversial and to date has not affected clinical decision-making. 47 Similarly, in SCCB, the expression of p53 varies from 37% to 80%, 40,41,53 yet prognosis appears poor in both p53 expressing and nonexpressing tumours. 54 …”